CSL Predicts US Flu-Shot Rebound as Seqirus Expands in Europe

A healthcare worker administers a flu shot in Los Angeles, California, US.

Photographer: Patrick T. Fallon/Bloomberg

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention.

A recovery in the US market is expected in the medium-term, Dave Ross, general manager of Seqirus, CSL’s vaccines unit, told analysts and investors in Chicago Tuesday, without giving a specific timeframe.